UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.1212-1217

2015

Volltextzugriff (PDF)

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

Annals of the rheumatic diseases, 2015-05, Vol.74 (5), p.890-896

2015

Volltextzugriff (PDF)

Prevalence of widespread pain and associations with work status: a population study

BMC musculoskeletal disorders, 2008-07, Vol.9 (1), p.102-102, Article 102

2008

Volltextzugriff (PDF)

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

Annals of the rheumatic diseases, 2007-10, Vol.66 (10), p.1339-1344

2007

Volltextzugriff (PDF)

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

BMJ (Online), 2013-04, Vol.346 (7905), p.f1939

International edition, 2013

Volltextzugriff (PDF)

Ten years with biologics: to whom do data on effectiveness and safety apply?

Rheumatology (Oxford, England), 2011-01, Vol.50 (1), p.204-213

2011

Volltextzugriff (PDF)

Does cancer that occurs during or after anti–tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site‐specific cancer survival in rheumatoid arthritis patients treated with biologic agents

Arthritis & rheumatology (Hoboken, N.J.), 2011-07, Vol.63 (7), p.1812-1822

2011

Volltextzugriff (PDF)

Chronic widespread musculoskeletal pain – A comparison of those who meet criteria for fibromyalgia and those who do not

European journal of pain, 2008-07, Vol.12 (5), p.600-610

2008

Volltextzugriff (PDF)

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

Arthritis and rheumatism, 2009-11, Vol.60 (11), p.3180-3189

2009

Volltextzugriff (PDF)

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

Arthritis and rheumatism, 2005-07, Vol.52 (7), p.1986-1992

2005

Volltextzugriff (PDF)

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

The Lancet (British edition), 2009-08, Vol.374 (9688), p.459-466

2009

Volltextzugriff (PDF)

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

Annals of the rheumatic diseases, 2009-05, Vol.68 (5), p.648-653

2009

Volltextzugriff (PDF)

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

The Lancet (British edition), 2012, Vol.379 (9827), p.1712-1720

2012

Volltextzugriff (PDF)

Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

Annals of the rheumatic diseases, 2011-03, Vol.70 (3), p.469-475

2011

Volltextzugriff (PDF)

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

Annals of the rheumatic diseases, 2005-10, Vol.64 (10), p.1421-1426

2005

Volltextzugriff (PDF)

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

Annals of the rheumatic diseases, 2005-10, Vol.64 (10), p.1414-1420

2005

Volltextzugriff (PDF)

The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

Arthritis research & therapy, 2014-01, Vol.16 (3), p.R127-R127

2014

Volltextzugriff (PDF)

Oligosaccharide mapping of proteoglycan-bound and xyloside-initiated dermatan sulfate from fibroblasts

Glycoconjugate journal, 1991-04, Vol.8 (2), p.108-115

1991

Volltextzugriff (PDF)

Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register

Annals of the rheumatic diseases, 2011-03, Vol.70 (3), p.516-519

2011

Volltextzugriff (PDF)

Binding of Transferrin to the Core Protein of Fibroblast Proteoheparan Sulfate

Proceedings of the National Academy of Sciences - PNAS, 1984-09, Vol.81 (18), p.5657-5661

1984

Volltextzugriff (PDF)

Altered dermatan sulfate proteoglycan synthesis in fibroblast cultures established from skin of patients with systemic sclerosis

Journal of rheumatology, 1996-08, Vol.23 (8), p.1398

1996

Volltextzugriff (PDF)

Structure and properties of dermatan sulphate proteoglycans

Biochemical Society transactions, 1991-11, Vol.19 (4), p.866

Cöster, L

1991

Volltextzugriff (PDF)

Structure of proteoheparan sulfates from fibroblasts. Confluent and proliferating fibroblasts produce at least three types of proteoheparan sulfates with functionally different core proteins

The Journal of biological chemistry, 1986-09, Vol.261 (26), p.12079-12088

1986

Volltextzugriff (PDF)

Intensive care unit acquired muscle weakness in COVID-19 patients

Intensive care medicine, 2020-11, Vol.46 (11), p.2083-2085

2020

Volltextzugriff (PDF)

Minimally important change, measurement error, and responsiveness for the Self-Reported Foot and Ankle Score

Acta orthopaedica, 2017-05, Vol.88 (3), p.300-304

2017

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Female
(26)
Male
(25)
Medicin Och Hälsovetenskap
(24)
Middle Aged
(24)
Aged
(20)
Clinical Medicine
(20)
Klinisk Medicin
(20)
Medical And Health Sciences
(20)
Rheumatology
(19)
Adult
(18)
Arthritis, Rheumatoid - Drug Therapy
(18)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(16)
Antirheumatic Agents - Therapeutic Use
(15)
Biological And Medical Sciences
(15)
Reumatologi Och Inflammation
(14)
Rheumatology And Autoimmunity
(14)
Sweden - Epidemiology
(13)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

Prevalence of widespread pain and associations with work status: a population study

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

Ten years with biologics: to whom do data on effectiveness and safety apply?

Does cancer that occurs during or after anti–tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site‐specific cancer survival in rheumatoid arthritis patients treated with biologic agents

Chronic widespread musculoskeletal pain – A comparison of those who meet criteria for fibromyalgia and those who do not

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

Oligosaccharide mapping of proteoglycan-bound and xyloside-initiated dermatan sulfate from fibroblasts

Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register

Binding of Transferrin to the Core Protein of Fibroblast Proteoheparan Sulfate

Altered dermatan sulfate proteoglycan synthesis in fibroblast cultures established from skin of patients with systemic sclerosis

Structure and properties of dermatan sulphate proteoglycans

Structure of proteoheparan sulfates from fibroblasts. Confluent and proliferating fibroblasts produce at least three types of proteoheparan sulfates with functionally different core proteins

Intensive care unit acquired muscle weakness in COVID-19 patients

Minimally important change, measurement error, and responsiveness for the Self-Reported Foot and Ankle Score

Aktive Filter

Suchergebnisse filtern